Investors Set Their Sights On Horizon Pharma
Horizon Pharma has emerged out of two transformative deals as a high-growth specialty pharma with four commercially available drugs. Now it is on track to achieve profitability in 2014, and investors are perking up to hear more about the company’s acquisitive strategy, which includes more aggressive dealmaking.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.